Medications for Neuromyelitis Optica
4 results
Enspryng (satralizumab)
(Satralizumab)Genentech Inc.
Usage: ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are positive for anti-aquaporin-4 (AQP4) antibodies.
Soliris (eculizumab)
(ECULIZUMAB)Alexion Pharmaceuticals Inc
Usage: SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit thrombotic microangiopathy, generalized myasthenia gravis (gMG) in patients aged six and older, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 positive adults.
Ultomiris (ravulizumab)
(ravulizumab)Alexion Pharmaceuticals Inc
Usage: ULTOMIRIS is indicated for treating adult and pediatric patients aged one month and older with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Additionally, it is used for adult patients with generalized myasthenia gravis (anti-AChR antibody-positive) and neuromyelitis optica spectrum disorder (AQP4 antibody-positive).
Uplizna (inebilizumab)
(Inebilizumab)Horizon Therapeutics USA, Inc.
Usage: UPLIZNA is indicated for treating neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 antibody positive and for treating Immunoglobulin G4-related disease (IgG4-RD) in adults.